Charitable Partner

An Exclusive Charitable Partnership

As breakthroughs in cancer immunotherapy are happening today, it is important to remember that they are
due in large part to basic research that has been going on for decades. While we are very proud to
support the public companies that are bringing these therapies to patients today, we also view it
as our obligation to support the early stage private research that will lead to breakthroughs of
tomorrow.

With that in mind, Loncar Investments has entered into an exclusive charitable partnership for the Loncar
Cancer Immunotherapy ETF (CNCR) with the Cancer Research Institute (CRI).

CRI is the leader in backing immunotherapy research, and so it is our honor to support them. Loncar
Investments will use royalties it receives as the exchange-traded fund’s index provider
to donate regular contributions to CRI that amount to 2 basis points, or 0.02%, of CNCR’s total assets.

“Today’s breakthroughs in cancer immunotherapy have emerged from decades of basic scientific research
funded by visionary benefactors, with the Cancer Research Institute at the forefront. As our
index supports public companies delivering these advances to patients, we want to foster that
critical early research as well. There is no better way to do that than to give to an immunotherapy
pioneer like CRI.”– Brad Loncar,
CEO, Loncar Investments

The partnership has been in existence since November of 2015. Loncar Investments has guaranteed a minimum donation of at least $10,000 per calendar year

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis
point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 25 securities that have a strategic focus on the area
of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be
found under the symbol “LCINDX” on the Bloomberg Professional service and other financial data providers.
One may not directly invest in an index.

The Loncar China BioPharma Index is an index of 28 securities that have a strategic focus on advancing China’s biopharma industry. Quotes for the index can be found under the symbol “LCHINA” on the Bloomberg Professional service and other financial data providers. One may not directly invest in an index.

Holdings are subject to change.

The Hong Kong Stock Exchange (HKEX) is the primary stock exchange in the Hong Kong Special Administrative Region of China. Nasdaq is one of the primary stock exchanges in the United States.

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before
investing. This and additional information can be found in the Fund’s prospectus, which may
be obtained at www.loncarfunds.com. Read the prospectus carefully before investing.

Investing involves risk. Principal loss is possible. The fund may trade at a premium or discount to NAV.
CNCR will invest in immunotherapy companies which are highly dependent on the development, procurement
and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s
valuation can also be greatly affected if one of its products is proven or alleged to be unsafe,
ineffective or unprofitable. The costs associated with developing new drugs can be significant, and
the results are unpredictable. The process for obtaining regulatory approval by the U.S. Food and
Drug Administration or other governmental regulatory authorities is long and costly and there can
be no assurance that the necessary approvals with be obtained and maintained. The Fund may invest
in foreign securities, which involve political, economic, currency risk, greater volatility, and
differences in accounting methods. The Fund is non-diversified meaning it may concentrate its assets
in fewer individual holdings than a diversified fund. Therefore, the Fund is more exposed to individual
stock volatility than a diversified fund. The Fund invests in smaller companies, which may have more
limited liquidity and greater volatility compared to larger companies. The Fund is not actively managed
and may be affected by a general decline in market segments related to the index. The fund invests
in securities included in, or representative of securities included in, the index, regardless of
their investment merits. The performance of the fund may diverge from that of the Index and may experience
tracking error to a greater extent than a fund that seeks to replicate an index. Shares are bought
and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions
will reduce returns.

RISK FOR THE CHNA ETF: The biopharmaceutical industry in China is strictly regulated and changes in such regulations, including banning or limiting certain products, may have a material adverse effect on the operations, revenues, and profitability of Biopharma Companies. The laws and regulations applicable to the process of administrative approval of medicine and its production in China require entities producing biopharma products to comply strictly with certain standards and specifications promulgated by the government. Changes in currency exchange rates and the relative value of non-U.S. currencies will affect the value of the investment. Currency exchange rates can be very volatile and can change quickly and unpredictably. Investments in non-U.S. securities involve certain risks that may not be present with investments in U.S. securities. For example, investments in non-U.S. securities may be subject to risk of loss due to foreign currency fluctuations or to political or economic instability. Investments in non-U.S. securities also may be subject to withholding or other taxes and may be subject to additional trading, settlement, custodial, and operational risks. These and other factors can make investments in the Fund more volatile and potentially less liquid than other types of investments. To the extent the Fund invests a significant portion of its assets in the securities of companies of a single country or region, such as China, it is more likely to be impacted by events or conditions affecting that country or region. The Fund is a recently organized, non-diversified management investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund. The Fund is not actively managed and the Fund's sub-adviser would not sell shares of an equity security due to current or projected underperformance of a security, industry or sector, unless that security is removed from the Index or the selling of shares of that security is otherwise required upon a reconstitution of the Index in accordance with the Index methodology. To the extent the Fund invests more heavily in particular sectors of the economy, its performance will be especially sensitive to developments that significantly affect those sectors."

Diversification may not protect against market risk.

Exchange Traded Concepts, LLC serves as the investment advisor, and Vident Investment Advisory, LLC serves
as a sub advisor to the fund. The Funds are distributed by Quasar Distributors, LLC, which is not affiliated
with Exchange Traded Concepts, LLC or any of its affiliates.